Price
No data yet.
Social Signal Score
Revenue
$10.01M+115.48%Company Profile
- CEO
- Jie Liu
- Sector
- Basic Materials
- Industry
- Steel
- Employees
- 167
- Beta
- 0.49
- Country
- CN
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 8.77
Financials
Revenue
$10.01M+115.5%Net Income
$952.8K-8.4%EBITDA
$1.51M-13.4%Free Cash Flow
$1.04M+364.9%EPS (diluted)
$0.01-84.7%Shares Outstanding (diluted)
73.29M+507.6%Operating Expenses
$1.94MCash & Debt
$1.89MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.60M | $1.94M | $0.03 |
| 2024 | $14.11M | $-1.88M | $-0.03 |
| 2023 | $16.00M | $864.7K | $0.07 |
| 2022 | $20.28M | $2.93M | $0.24 |
| 2021 | $21.71M | $3.20M | $0.27 |
| 2020 | $11.16M | $2.42M | $0.20 |
| 2019 | $9.29M | $2.08M | $0.17 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HLP's reported EPS growth of -26.6% a year over 6 years. Historical EPS growth of -27% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.01
- Implied price
- $0.46
- Return from $2.55
- -29.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.23 — -91.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 27 | 33 | 39 | 45 | 51 |
|---|---|---|---|---|---|
| -25.0% | -41.9% | -39.5% | -37.4% | -35.6% | -34.0% |
| -20.0% | -38.0% | -35.4% | -33.2% | -31.3% | -29.6% |
| -15.0% | -34.1% | -31.4% | -29.1% | -27.0% | -25.2% |
| -10.0% | -30.2% | -27.4% | -24.9% | -22.7% | -20.8% |
| -5.0% | -26.3% | -23.3% | -20.7% | -18.4% | -16.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·17h ago·Neutral
Hongli Group Inc. Announces Appointment of Mr. Michael W. WEIFANG, China, Oct. 5, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced a leadership transition within its Board of Directors (the "Board"). Effective September 29, 2026, Mr.
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by d…
View source ↗ - Newsseekingalpha.com·45d ago·Positive
…t a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004 (IM DMT) data suggest efficacy and durability when used as adjunctive therapies, although this comes from small trials. Helus is conducting a phase III trial for HLP003, which could validate its clinical profile and reduce the valuation discount relative to peers.
View source ↗ - Newsprnewswire.com·54d ago·Negative
Hongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement WEIFANG, China, Aug. 12, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on August 7, 2026, it received a notification letter from Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated August 7, 2026, stating that the Company has regained compliance with the requirement to maint
View source ↗
Congress trades
No disclosed congressional trades in HLP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.